↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Caribou Biosciences: Rotting at the dock (four or more warning signs)Rotting at the dock

Caribou Biosciences $CRBU

Grew revenue 11.7% in FY2025 to $11 million, operating margin -1329% against a -15.8% median for biological products, (no diagnostic substances), equity 69.7% of assets.

Last filing10-Q, 5 Nov 2026

Next year, 80%$3M–$40M
Growth, on the year11.7%
Operating margin−1329.4%
Equity of assets69.7%
Credibility63%
Track record2 of 3
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up Caribou Biosciences, Inc. ($CRBU). Last filing: 10-Q, 2026-11-05. 8 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $11.2M (FY2025). Experience: revenue up 11.7% on the year, up 3.8% a year over 4 years; operating margin -1329.4%, up from -1667.2%. Soundness: equity 69.7% of assets, return on equity -121.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.2M and $40.1M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7M to $48.0M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -1329.4% against a -15.8% median; growth 11.7% against 21.4%.

Read from its own SEC filings · nothing written, nothing inferred

Caribou Biosciences, Inc. against its own record and its peers
Operating marginPeer median -15.8%-1329.4%Revenue, on the yearPeer median 21.4%11.7%Equity of assetsPeer median 58.6%69.7%Return on equityPeer median -6.5%-121.2%Gold tick: the median of 25–31 peers with $50M+ revenue in biological products, (no diagnostic substances)

Speed and cash · fiscal 2025

Cash Compass🍂 Fading · slow and jumpy, lagging its peers
Inside viewTurns -200.0% of revenue into operating cash; revenue shrinking 7.0% a year over three years; no common dividend.
Outside viewAmong under $50M companies: 8th percentile for cash, 35th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)−$111M · $102M · $5M · −$112M
Investment book (cash · short · long)$12M · $127M · $4M · current ratio 5.71 · unrealized $0M
Revenue swing · equity of assets78.5% · 69.7%

Caribou Biosciences is growing slower than its size class, with revenue that swings more. Its own audited SEC figures.

The figures, as filed

Fiscal year end2025-12-31
Revenue$11M
Revenue, on the year11.7%
Revenue, a year over the record3.8%
Operating margin−1329.4%
Operating margin, prior year−1667.2%
Net margin−1327.4%
Research and development$109M · 980.7% of revenue
Total debt—
Equity of assets69.7%
Return on equity−121.2%
Payout of profit—
Dividend per share—
Earnings per share$-1.59
Book value per share$1.31
Revenue per share$0.12
Shares outstanding93,389,283
Audited years read5

Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).

Classic signals · fiscal 2025Altman Z″ -9.88 distress zone 1968Piotroski F 3 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -15.2% earnings backed by cash 1996DuPont ROE -79% = margin -1327.4% × turns 0.05 × leverage 1.3

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborCaribou Biosciences sails as Rotting at the dock5 warning signs

Health watch · 12 monthsRestructuring or exit costsDirector or officer change

Versus peersoperating margin −1329.4% vs a −15.8% median · revenue growth 11.7% vs 21.4% · cash beats 8% of its size class · growth beats 35% 31 biological products filers

Trend · last year to this▲operating margin −1667.2% → −1329.4% · ▲revenue $10.0M → $11.2M · 5-year revenue: $9.6M · $13.9M · $34.5M · $10.0M · $11.2M

See all 65 biological products companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipExelixisEXELNew ship37.6%7.0%$2.3B
2New shipHalozyme TherapeuticsHALONew ship33.6%37.6%$1.4B
3New shipNeurocrine BiosciencesNBIXNew ship21.6%21.4%$2.9B
4New shipVaxartVXRTNew ship7.6%726.7%$237.3M
5Sound shipMaze TherapeuticsMAZESound ship34.4%—$167.5M
6Sound shipAmgenAMGNSound ship24.7%10.0%$36.8B
7Sound shipRepligenRGENSound ship7.5%16.4%$738.3M
8Sound shipExozymesEXOZSound ship−2563.5%—$0.1M
9Sound shipLexeo TherapeuticsLXEOSound ship−9252.1%—$0.7M
10Sound shipCalidi BiotherapeuticsCLDISound ship−51395.6%—$0.0M
11Weathered boatMonte Rosa TherapeuticsGLUEWeathered boat−43.8%63.5%$123.7M
12Weathered boatAlpha CognitionACOGWeathered boat−221.7%—$10.2M
13Weathered boatHumacyteHUMAWeathered boat−5306.0%—$2.0M
14Weathered boatCandel TherapeuticsCADLWeathered boat−27777.6%0.0%$0.1M
15Weathered boatRevolution MedicinesRVMDWeathered boat——$0.0M
16Weathered boatScholar Rock HoldingSRRKWeathered boat—−100.0%$0.0M
17Weathered boatAllogene TherapeuticsALLOWeathered boat—−100.0%$0.0M
18Weathered boatInhibikase TherapeuticsIKTWeathered boat—−100.0%$0.0M
19Weathered boatNKGen Biotech1845459Weathered boat—−100.0%$0.0M
20Old boatChampions OncologyCSBROld boat−1.9%4.4%$59.4M
21Old boatFennec PharmaceuticalsFENCOld boat−14.1%−6.1%$44.6M
22Old boatTarsus PharmaceuticalsTARSOld boat−15.7%146.7%$451.4M
23Old boatCentury Therapeutics, Inc.IPSCOld boat−15.8%1556.8%$109.2M
24Old boatCurisCRISOld boat−60.5%−13.4%$9.4M
25Old boatRegenxbioRGNXOld boat−94.6%104.5%$170.4M
26Old boatInvivydIVVDOld boat−104.0%110.5%$53.4M
27Old boatPelthos TherapeuticsPTHSOld boat−193.1%—$16.8M
28Old boatDyadic InternationalDYAIOld boat−232.8%−11.6%$3.1M
29Old boatX4 PharmaceuticalsXFOROld boat−247.4%1250.5%$35.1M
30Old boatLenz TherapeuticsLENZOld boat−477.5%—$19.1M
31Old boatAlectorALECOld boat−741.3%−79.1%$21.0M
32Old boatRecursion PharmaceuticalsRXRXOld boat−867.9%26.9%$74.7M
33Old boatAligos TherapeuticsALGSOld boat−4024.9%−39.5%$2.2M
34Old boatPrime MedicinePRMEOld boat−4498.1%55.3%$4.6M
35Old boatCardiff OncologyCRDFOld boat−8256.3%−13.2%$0.6M
36Old boatInhibrx BiosciencesINBXOld boat−10386.5%550.0%$1.3M
37Old boatCrispr Therapeutics AGCRSPOld boat−18933.6%−90.6%$3.5M
38Old boatEntera BioENTXOld boat−27450.0%−76.8%$0.0M
39Old boatBioatlaBCABOld boat−32146.7%—$0.3M
40Old boatAtyr PharmaATYROld boat−40856.3%−19.1%$0.2M
41Old boatInmune BioINMBOld boat−94766.0%257.1%$0.1M
42Old boatCreative Medical Technology HoldingsCELZOld boat−102380.2%−45.5%$0.0M
43Old boatSenti Biosciences HoldingsSNTIOld boat−312631.8%—$0.0M
44Old boatEloxx PharmaceuticalsELOXOld boat—−100.0%$0.0M
45Old boatPharmacyte BiotechPMCBOld boat——$0.0M
46Old boatArtiva BiotherapeuticsARTVOld boat—−100.0%$0.0M
47Rotting at the dockZeo ScientifiXZEOXRotting at the dock−103.6%12.5%$5.2M
48Rotting at the dockMeiraGTx HoldingsMGTXRotting at the dock−130.2%144.6%$81.4M
49Rotting at the dockModernaMRNARotting at the dock−158.1%−39.9%$1.9B
50Rotting at the dockLineage Cell TherapeuticsLCTXRotting at the dock−251.6%53.2%$14.6M
51Rotting at the dockSangamo TherapeuticsSGMOQRotting at the dock−306.5%−31.6%$39.6M
52Rotting at the dockVoyager TherapeuticsVYGRRotting at the dock−326.6%−49.5%$40.4M
53Rotting at the dockCoherus Oncology, Inc.CHRSRotting at the dock−429.5%59.8%$42.2M
54Rotting at the dockVir BiotechnologyVIRRotting at the dock−699.2%−7.6%$68.6M
55Rotting at the dockScilex Holding CompanySCLXRotting at the dock−1143.7%−46.5%$30.3M
56Rotting at the dockSurrozen, Inc./DESRZNRotting at the dock−1210.6%−67.4%$3.5M
57Rotting at the dockTscan TherapeuticsTCRXRotting at the dock−1315.4%266.7%$10.3M
58Rotting at the dockCaribou BiosciencesCRBU · this companyRotting at the dock−1329.4%11.7%$11.2M
59Rotting at the dockOcugenOCGNRotting at the dock−1425.7%8.8%$4.4M
60Rotting at the dockFate TherapeuticsFATERotting at the dock−2222.4%−51.2%$6.6M
61Rotting at the dockPluriPLURRotting at the dock−2454.5%−24.0%$1.0M
62Rotting at the dockAbpro HoldingsABPORotting at the dock−5421.3%50.0%$0.2M
63Rotting at the dockVivoSim LabsVIVSRotting at the dock−8768.7%−9.0%$0.1M
64Rotting at the dockAim ImmunotechAIMRotting at the dock−13254.5%−48.2%$0.1M
65Rotting at the dockProKidneyPROKRotting at the dock−18477.8%1075.0%$0.9M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Tied up at the dock.

🌊 Visit the Bay →
The warning signs
  • Filed restructuring or exit costs in the last 12 months
  • Slow and jumpy growing slower than its size class, with revenue that swings more
  • Operating cash flow was negative
  • Operating loss a margin of -1329.4% in FY2025
  • Revenue is hard to predict its 80% range is ±85%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 448

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from Caribou Biosciences's own SEC filings and test each one against the public companies in its field, here pharmaceutical preparations. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 448, Caribou Biosciences's odds of thriving come to 28%, against about 37% for the typical filer. It meets 0 of 5 success points.

448The Trillion Score
28%modeled odds of thriving over three years
HighFall Risk
#141 of 182rank in its field
#2,156 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 31 of every 100 did.

31%Under 450This company: 44835%450 to 49938%500 to 54944%550 to 59957%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: High

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.

MoneyIt burned about 1007 cents of free cash on each sales dollar after paying for its plants and equipment. Its cash would cover that burn for about 0.1 years.cash negative over five years
SwingsIn its worst fifth of years, sales fell about 100% a year.-100.0% a year
Filed eventsIn the last two years it told the SEC about 2 filings on layoffs, write-downs or cyber incidents, and 3 filings on leadership or auditor changes.5

The eight success points

PointWhat it meansPlace in field
SpeedSales grew slower than much of its field.17 of 100Not yet
SteadinessGrowth swung a lot for what it delivered.28 of 100Not yet
Price premiumIt keeps less of each sales dollar than the leaders in its field.8 of 100Not yet
Margin stays above the fieldIts margin has not held above the field for long.13 of 100Not yet
Moat half-lifeNot filed.
Brand spend yieldNot filed.
Learning curveNot filed.
Climb in the fieldIt has not been moving up the size ranks in its field.57 of 100Not yet

The actuarial view

CredibilityWith 7 years of filings, the record earns 42% of the weight. The rest stays at the middle of the field.0.42
Severe decline, class DAbout 34 of every 100 companies with this many points fell 30% or stopped reporting within three years.34.3%
Actual vs expectedSales are 36% lower than if it had simply kept pace with its field.0.64

Top of its field: #1 Mannkind · #2 Biocryst Pharmaceuticals · #3 Corcept Therapeutics · #4 Kiniksa Pharmaceuticals International · #5 Eli Lilly

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.